Navigating Late Line R/R Multiple Myeloma: Treatment Landscape, Patient Care, and Quality of Life : Episode 4
Opinion
Video
Current Treatment Landscape for Late-Line RRMM
Author(s):
Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates and clinical trials of emerging agents, with treatment selection highly individualized based on prior therapies, resistance patterns and patient-specific factors like comorbidities, quality of life considerations and treatment goals.
Video Player is loading.
Video content above is prompted by the following:
- What is the current treatment landscape for patients who have late-line RRMM?
Related Videos
Navigating RRMM: Helpful Resources and Advice for Patients Facing Disease Progression
Guidance for Caregivers: Supporting a Loved One Through Late-Line RRMM
Effective Communication Strategies: Sharing Concerns With Your Medical Team in Late-Line RRMM
Addressing the Most Common Concerns Patients and Caregivers Have in Late-Line RRMM
Lifestyle Modifications That Have Been Helpful in RRMM
Aligning Treatment Goals: Key Considerations for Patients and Caregivers in Late-Line RRMM
Balancing Efficacy and Quality of Life in Late-Line RRMM
Balancing Benefits and Risks: Patients’ Experiences With Newer Therapies and Side Effects in Late-Line RRMM
Recent Updates in CAR-T Cell Therapy and Their Impact in Clinical Practice in RRMM
Recent Updates in Bispecifics and Their Use in Clinical Practice
